Latest Filgrastim Stories
THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim(TM).
LEAMINGTON SPA, United Kingdom, June 10 /PRNewswire-FirstCall/ -- Hospira announced today that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1).
Multicenter trial led by St Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients.
DALLAS, February 16, 2010 /PRNewswire/ -- - ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( http://www.reportsandreports.com/market-reports/pipeline-commercial-insight-s upportive-care-in-oncology-innova/) Market Research Report in its store (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into...
LAKE FOREST, Ill., Sept. 30 /PRNewswire-FirstCall/ -- Hospira, Inc.
U.S. scientists say a human growth factor used to stimulate blood stem cells to proliferate in bone marrow can also reverse memory impairment in mice. Researchers at the University of South Florida and Haley Hospital, both in Tampa, Fla., genetically altered mice to develop Alzheimer's disease.
A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A
Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics.
By Bill Berkrot NEW YORK (Reuters) - Johnson & Johnson has sued Amgen, accusing the world's largest biotechnology company of hampering sales of J&J's anemia drug, Procrit, by using anti-competitive practices in the way it sells its own anemia drugs to physicians.
- A transitional zone between two communities containing the characteristic species of each.